Additionally, EMT has been recognized as a potential mechanism in tumor progression, characterized by the loss or down-regulation of epithelial markers (E-cadherin) and up-regulation of mesenchymal markers (Vimentin). The gene discussed is CDH1; the disease is neoplasm.